- In April 2023, Medtronic announced the U.S. launch of its Simplera Sync™ integrated all-in-one continuous glucose monitor (CGM) and insulin pump. This innovative device simplifies diabetes management by combining continuous glucose sensing and automated insulin delivery in a single, easy-to-use system, aiming to improve glycemic control and reduce the burden of daily management for individuals with diabetes in North America.
- In March 2023, Abbott received FDA clearance for its FreeStyle Libre® 3 system for use in children as young as 2 years old. This expanded indication allows more young individuals with diabetes in North America to benefit from the real-time glucose monitoring capabilities of the FreeStyle Libre 3, aiding in better glucose management and improved quality of life for pediatric patients and their caregivers.
- In March 2023, Insulet Corporation announced the expansion of its Omnipod® 5 Automated Insulin Delivery System to include compatibility with the Dexcom G7 CGM in the U.S. This integration provides users in North America with more options for personalized and automated insulin delivery, enhancing the accuracy and convenience of diabetes management through seamless communication between the pump and CGM.
- In February 2023, Novo Nordisk announced the U.S. availability of its next-generation smart insulin pen, NovoPen® 6. This connected pen records insulin doses and timing, which can be shared with compatible diabetes management apps, helping individuals in North America to track their insulin usage and improve adherence to their treatment plans.
- In January 2023, Dexcom launched its G7 CGM system in Canada, offering individuals with diabetes in North America (specifically Canada in this instance) a smaller, more discreet, and accurate real-time continuous glucose monitoring system with direct-to-smartphone connectivity and enhanced alert customization. This launch aimed to improve the accessibility and user experience of CGM technology in the Canadian market.
